Reviva Reports Full Year 2024 Financial Results and Recent Business Highlights
-- Favorable long-term safety and robust broad-spectrum efficacy sustained over 1-year for once daily brilaroxazine in open-label extension (OLE) trial --
-- Registrational Phase 3 RECOVER-2 trial initiation for brilaroxazine expected mid-2025 --
-- Full data set from RECOVER OLE expected in Q2 2025 --
CUPERTINO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system $(CNS)$, inflammatory and cardiometabolic diseases, today reported financial results for the full year ended December 31, 2024 and summarized recent business highlights.
"Our late stage brilaroxazine program has consistently shown what we believe to be robust broad-spectrum efficacy across all major symptom domains of schizophrenia and a well-tolerated safety profile. Importantly, initial long-term data from our OLE study showed that these favorable efficacy and safety findings were sustained over time. We expect to report the full data set from the RECOVER OLE study, which will also include vocal and blood biomarker data as additional independent measures of efficacy, in the second quarter of 2025," said Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva. "Brilaroxazine has a robust data package that includes a successful placebo-controlled Phase 3 trial with a long-term open label extension for up to 1-year, a successful Phase 2 study and a compelling drug-drug interaction study. We believe the differentiated potential of once daily brilaroxazine to address all major unmet needs for patients with schizophrenia continues to be strong, and we are targeting a potential New Drug Application (NDA) submission for brilaroxazine in the fourth quarter of 2026."
Fourth Quarter 2024 and Recent Business Highlights
Clinical Program Highlights
-- Positive preliminary topline data for the OLE portion of the Company's
ongoing Phase 3 RECOVER study evaluating the long-term safety and
tolerability of brilaroxazine in patients with schizophrenia announced
(December 2024)
-- Robust broad-spectrum efficacy that was sustained over 1 year
-- Dose dependent efficacy, with decreases in PANSS total scores of
-15.2, -18.6 and -20.8 points at the 15, 30, and 50 mg doses
respectively, from baseline to end-of-treatment at 52 weeks (1
year)
-- Pooled data of brilaroxazine at the 15, 30, and 50 mg doses (N =
113) demonstrated clinically meaningful and sustained long-term
(1-year) efficacy for schizophrenia:
-- PANSS Total scores: 18.6-point decrease (71.6 -> 53), p <=
0.0001
-- PANSS Positive Symptoms: 5.2-point decrease (17.7 ->12.5),
p <= 0.0001
-- PANSS Negative Symptoms: 4.5-point decrease (19.5 ->15.0),
p <= 0.0001
-- Generally well tolerated with no single side effect >5%
-- Favorable compliance, with a discontinuation rate of 35%,
primarily due to withdrawal of consent (22%), participant lost to
follow up (7%), and treatment-related adverse events $(TRAE)$ (1.6%)
-- 15.2% reported at least one TRAE, which were mostly mild (12.2%)
or moderate (3%) in severity and transient in nature
-- Most common TRAEs >=1% were weight increase (3.2%), insomnia
(1.8%) and somnolence (1.6%)
-- No drug-related serious adverse events (SAEs) observed or major safety
concerns reported for brilaroxazine after up to 1 year of treatment
Corporate Highlights
-- Positive topline data from the long-term OLE portion of the Phase 3
RECOVER study evaluating brilaroxazine in schizophrenia presented as an
oral presentation on March 30th at the 2025 Congress of the Schizophrenia
International Research Society (SIRS) in Chicago, Illinois
-- Completed a public follow-on offering with aggregate gross proceeds of
approximately $18.0 million (December 2024)
-- Positive speech latency data for brilaroxazine in schizophrenia from the
Phase 3 RECOVER trial presented as a poster presentation at the Central
Nervous System $(CNS.UK)$ Summit 2024 on November 12th in Boston,
Massachusetts
Anticipated Milestones and Events
-- Full data analysis of the OLE trial including long-term safety,
tolerability and efficacy, as well as vocal and blood biomarker data
expected in Q2 2025
-- Initiation of registrational Phase 3 RECOVER-2 trial evaluating
brilaroxazine for the treatment of schizophrenia expected in mid-2025,
subject to receipt of additional financing
-- Potential NDA submission for brilaroxazine in schizophrenia targeted for
the fourth quarter of 2026
-- Investigational new drug application $(IND.AU)$ submission for liposomal-gel
formulation of brilaroxazine in psoriasis expected later in 2025
-- Pursue partnership opportunities for the development of our pipeline
Financial Results for 2024
The Company reported a net loss of approximately $29.9 million, or $0.90 per share, for the fiscal year ended December 31, 2024, compared to a net loss of approximately $39.3 million, or $1.65 per share, for the fiscal year ended December 31, 2023.
As of December 31, 2024, the Company's cash and cash equivalents totaled approximately $13.5 million compared to approximately $23.4 million as of December 31, 2023.
About Reviva
Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva's current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva's pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act, as amended, including those relating to the Company's 1-year open label extension (OLE) trial evaluating the long-term safety and tolerability for brilaroxazine in schizophrenia, the registrational Phase 3 RECOVER-2 trial, the Company's expectations regarding the anticipated clinical profile of its product candidates, including statements regarding anticipated efficacy or safety profile, and those relating to the Company's expectations, intentions or beliefs regarding matters including product development and clinical trial plans, clinical and regulatory timelines and expenses, planned or intended additional trials or studies and the timing thereof, planned or intended regulatory submissions and the timing thereof, trial results, market opportunity, ability to raise sufficient funding, competitive position, possible or assumed future results of operations, business strategies, potential opportunities for development including partnerships, growth or expansion opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.
These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential, "predict," "project, " "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's most recent Annual Report on Form 10-K and the Company's other filings from time to time with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD
www.revivapharma.com
Investor Relations Contact:
LifeSci Advisors, LLC
Bruce Mackle
bmackle@lifesciadvisors.com
REVIVA PHARMACEUTICALS HOLDINGS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
December 31, December 31,
2024 2023
Assets
Cash and cash equivalents $ 13,476,331 $ 23,367,456
Prepaid clinical trial costs 540,601 78,295
Prepaid expenses and other
current assets 666,435 254,637
------------ ------------
Total current assets 14,683,367 23,700,388
Non-current prepaid clinical
trial costs 819,721 --
------------ ------------
Total Assets $ 15,503,088 $ 23,700,388
============ ============
Liabilities and Stockholders'
Equity
Liabilities
Short-term debt $ 458,154 $ --
Accounts payable 6,283,430 3,849,108
Accrued clinical expenses 6,723,719 11,966,812
Accrued compensation 635,587 958,607
Other accrued liabilities 500,616 400,490
------------ ------------
Total current liabilities 14,601,506 17,175,017
------------ ------------
Warrant liabilities 89,010 806,655
------------ ------------
Total Liabilities 14,690,516 17,981,672
------------ ------------
Commitments and contingencies
Stockholders' Equity
Common stock, par value of
$0.0001; 315,000,000 shares
authorized; 46,579,199 and
27,918,560 shares issued and
outstanding as of December
31, 2024 and 2023,
respectively 4,658 2,792
Preferred Stock, par value of
$0.0001; 10,000,000 shares
authorized; 0 shares issued
and outstanding as of
December 31, 2024 and 2023 -- --
Additional paid-in capital 165,080,964 140,070,172
Accumulated deficit (164,273,050) (134,354,248)
------------ ------------
Total stockholders' equity 812,572 5,718,716
Total Liabilities and
Stockholders' Equity $ 15,503,088 $ 23,700,388
============ ============
REVIVA PHARMACEUTICALS HOLDINGS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
Year Ended December 31,
------------------------------
2024 2023
-----------
Operating expenses
Research and development $ 22,907,368 $ 31,419,817
General and administrative 7,891,521 8,083,819
----------- -----------
Total operating expenses 30,798,889 39,503,636
----------- -----------
Loss from operations (30,798,889) (39,503,636)
Other income (expense)
Gain (loss) on remeasurement
of warrant liabilities 717,645 (239,216)
Interest expense (18,497) (33,725)
Interest income 361,369 398,413
Other (expense) income, net (160,916) 134,276
----------- -----------
Total other income, net 899,601 259,748
----------- -----------
Loss before provision for
income taxes (29,899,288) (39,243,888)
Provision for income taxes 19,514 16,949
----------- -----------
Net loss $(29,918,802) $(39,260,837)
=========== ===========
Net loss per share:
Basic and diluted $ (0.90) $ (1.65)
=========== ===========
Weighted average shares
outstanding
Basic and diluted 33,147,424 23,798,203
(END) Dow Jones Newswires
March 31, 2025 16:05 ET (20:05 GMT)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.